Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 17, 2026International Journal of Clinical OncologyOpen Access

Efficacy and safety of subcutaneous mosunetuzumab plus polatuzumab vedotin in patients with relapsed/refractory large B-cell lymphoma: Japan subgroup analysis of the phase III SUNMO trial

View Full Paper
Ask AI
Bookmark
Share

Authors

DMDai MaruyamaHGHideki GotoTKTakahiro Kumode

Discussion

Loading...

Member takes

Overview

Randomized trial shows improved efficacy of Mosun-Pola in relapsed large B-cell lymphoma, indicating a potential new treatment option.

Key Points

  • This research aims to evaluate the efficacy and safety of Mosun-Pola in patients with relapsed/refractory large B-cell lymphoma from a Japan subgroup.
  • Patients were randomized 2:1 to receive Mosun-Pola or R-GemOx.
  • Dual primary endpoints included overall response rate and progression-free survival (PFS).
  • Subgroup data from 16 patients enrolled from Japan were analyzed.
  • 100% response rate in patients receiving Mosun-Pola (n=9) compared to 57.1% (n=4/7) for R-GemOx.
  • Median PFS was 16.2 months for Mosun-Pola versus 3.8 months for R-GemOx (HR: 0.42; 95% CI: 0.07–2.63).
  • Cytokine release syndrome occurred in 5 Mosun-Pola patients, all grade 1 and resolved.

Cite This Study

Maruyama et al. (2026) studied this question.

synapsesocial.com/papers/6a323f5ed50b63ecad207fa8https://doi.org/10.1007/s10147-026-03042-x
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Mosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory/relapsed large B-cell lymphoma: primary results of the phase 3 SUNMO trial2025 · 22 citations
  2. 2A Randomized Phase <scp>II</scp> Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B‐Cell Lymphoma2026 · 1 citations
  3. 3Fixed-duration intravenous mosunetuzumab plus polatuzumab vedotin combination therapy continues to demonstrate durable responses in patients with large B-cell lymphoma: 3-year follow-up from a Phase Ib/II study2025 · 1 citations
  4. 4Mosunetuzumab with polatuzumab vedotin: Subgroup analyses in patients (pts) with primary refractory or early relapsed large B-cell lymphoma (LBCL).2024 · 2 citations
  5. 5Mosunetuzumab plus polatuzumab vedotin (Mosun-Pola) versus rituximab, gemcitabine and oxaliplatin (R-GemOx) in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL): Updated efficacy and safety from the phase 3 SUNMO study including in second-line (2L) versus third-line plus (3L+) patient subgroups.2026